Groupe Bruxelles Lambert (GBLB) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
13 Jun, 2025Strategy and performance
Active strategy execution in H1 2024 included dynamic asset rotation, notably €630m net realized gains from partial adidas stake sale and €123m value creation in private assets.
Ongoing value creation from GBL Capital (+€139m) and preservation of a solid balance sheet with LTV at 7.4%.
Dividend per share for FY 2024 significantly increased to €5.00, subject to shareholder approval.
Listed assets (61% of portfolio) showed strong performance, with adidas, SGS, Imerys, Concentrix, and Umicore all executing strategic initiatives and reporting positive outlooks.
Private assets (20% of portfolio) delivered robust growth, with Affidea, Sanoptis, and Canyon all reporting double-digit organic sales increases and value creation.
Financial update
H1 2024 consolidated net result was €279m, down from €450m in H1 2023, mainly due to lower contributions from operating companies and negative mark-to-market effects.
Cash earnings reached €333m, reflecting lower net dividends from investments but a significant contribution from GBL Capital.
Net Asset Value (NAV) per share was €113.90 at June 30, 2024, rising to €116.19 by end-August, driven by positive share price movements in key holdings.
Liquidity profile remains strong with €3.8bn available and a low LTV of 7.4%.
Outlook
Dividend per share for FY 2024 set at €5.00, an 82% increase versus FY 2023, with a yield of 7.5%.
Focus on value creation, financial discipline, and ESG commitment, with continued support for portfolio companies' growth and strategic development.
Cash returns to shareholders will combine dividends and share buybacks.
Strategic update on mid-term trajectory scheduled for November 7, 2024.
Latest events from Groupe Bruxelles Lambert
- NAV per share up 3.8%, €1.1bn capital gains, €5.00 dividend, and double-digit TSR targeted.GBLB
Q3 2024 & Strategy Update16 Jan 2026 - Zero net debt, leadership change, 80% dividend hike, and strategic pivot to private assets.GBLB
AGM 202529 Nov 2025 - Portfolio simplification, strong healthcare growth, and enhanced shareholder returns marked the period.GBLB
Q3 20257 Nov 2025 - Record dividend, €0.8bn disposals, and private asset growth drove robust shareholder returns.GBLB
Q2 20258 Sep 2025 - NAV per share remained strong as asset rotation and dividend growth drove performance.GBLB
Q2 202413 Jun 2025 - NAV per share at €111.17, dividend up 82%, and private assets drive portfolio growth.GBLB
Q1 20255 Jun 2025 - 82% dividend hike and private asset growth drive mid-term value creation and TSR.GBLB
Q4 20245 Jun 2025